Mechanisms of Resistence of New Target Drugs in Acute Myeloid Leukemia
New drugs targeting single mutations have been recently approved for Acute Myeloid Leukemia (AML) treatment, but allogeneic transplant still remains the only curative option in intermediate and unfavorable risk settings, because of the high incidence of relapse. Molecular analysis repertoire permits...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Book Chapter |
| Language: | English |
| Published: |
IntechOpen
2020
|
| Subjects: | |
| Online Access: | https://www.intechopen.com/chapters/74391 |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: Mechanisms of Resistence of New Target Drugs in Acute Myeloid Leukemia
- Roads of Drug Resistance in Acute Myeloid Leukemia – Is It a Dead End?
- Target Therapy in Acute Myeloid Leukemia
- New Molecular Markers in Acute Myeloid Leukemia
- Pediatric Acute Myeloid Leukemia
- Therapy of Acute Myeloid Leukemia
- Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia by Immunomodulatory and Epigenetic Drugs